Plain-English translation of NCT06456515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether Regorafenib and Sintilimab, two cancer-fighting medications given together with electroacupuncture (a form of acupuncture), can help treat advanced colorectal cancer that has not responded to previous chemotherapy treatments. The study wants to learn whether this combination can slow or stop cancer growth and what side effects people may experience. You would be one of 30 patients receiving this combination therapy.
Many patients with advanced colorectal cancer run out of standard chemotherapy options, and their cancer continues to grow. This trial exists to see if this medication combination, paired with acupuncture, might offer a new hope for people in this situation.
You likely qualify if…
You likely don't qualify if…
You would take one medication by mouth for 2 weeks, then stop for 1 week, in a repeating cycle. You would also receive the second medication through an IV every 3 weeks. Around each IV infusion, you would receive electroacupuncture treatments—three sessions in the first week, then one session per week for the following 2 weeks. The entire study would involve ongoing visits to the hospital or clinic to receive these treatments and have blood tests to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China